TEK and prostate carcinoma: Here, we demonstrated for the first time that the addition of exogenous Ang-1 was able to restore the CSC and quiescence markers in prostate cancer cells after treating with γ-T3, further confirming that Ang-1/Tie-2 acts as a downstream target of γ-T3.